Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases

NCT05003986 is registered in ClinicalTrials.gov with Travere Therapeutics, Inc. as lead sponsor.

NCT NCT05003986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05003986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases
Lead sponsor
Travere Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 12, 2021
Completion date
April 12, 2027
Enrollment
67 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome, focal segmental glomerulosclerosis, iga vasculitis, immunoglobulin a nephropathy, minimal change disease